Inflammatory bowel diseases and the clinical course of coronavirus disease 2019 - a Polish single-centre experience from the pre-vaccine era.

IF 1.7 Q3 GASTROENTEROLOGY & HEPATOLOGY

Przegla̜d Gastroenterologiczny Pub Date : 2023-01-01 Epub Date: 2023-12-08 DOI:10.5114/pg.2023.133479

Estera Banasik, Agnieszka Dobrowolska, Barbara Kołodziejczak, Piotr Eder

{"title":"Inflammatory bowel diseases and the clinical course of coronavirus disease 2019 - a Polish single-centre experience from the pre-vaccine era.","authors":"Estera Banasik, Agnieszka Dobrowolska, Barbara Kołodziejczak, Piotr Eder","doi":"10.5114/pg.2023.133479","DOIUrl":null,"url":null,"abstract":"Introduction: The data on the relationship between inflammatory bowel diseases (IBD) and the course of COVID-19 from East-Central Europe are scarce.Aim: To assess the frequency of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in IBD patients and the impact of IBD on the COVID-19 course from the perspective of a Polish tertiary centre.Material and methods: Data on SARS-CoV-2 infection were retrospectively collected among IBD patients hospitalized in a Polish tertiary centre from March 2020 to May 2021. A questionnaire was used assessing the IBD characteristics, other comorbidities, and the course of COVID-19.Results: Among 350 patients, SARS-CoV-2 infection was diagnosed in 32 (9%). Severe COVID-19, defined as the need for hospitalization, was reported in 6 (19%) and mild in 26 (81%) cases. Compared to the mild COVID-19 course, patients with a severe course more often showed a higher IBD activity (3 points [IQR 2.25-3] vs. 1 point [IQR 0-2] in a semi-quantitative scale, p = 0.002), more often received steroids (67% vs. 11%, p = 0.02), and were not treated with biologics (0% vs. 46%, p = 0.07). There was a correlation between the duration of symptomatic infection and the number of comorbidities (r = 0.4, p = 0.04). No death or short-term COVID-19 complications were reported. In 25% of cases, SARS-CoV-2 infection caused new gastrointestinal symptoms.Conclusions: IBD is not a risk factor for SARS-CoV-2 infection. Steroids and higher IBD clinical activity may increase the risk of severe COVID-19. The prognosis for COVID-19 in our cohort was good. SARS-CoV-2 infection was a common cause of gastrointestinal symptoms.","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10985744/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Przegla̜d Gastroenterologiczny","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/pg.2023.133479","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The data on the relationship between inflammatory bowel diseases (IBD) and the course of COVID-19 from East-Central Europe are scarce.

Aim: To assess the frequency of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in IBD patients and the impact of IBD on the COVID-19 course from the perspective of a Polish tertiary centre.

Material and methods: Data on SARS-CoV-2 infection were retrospectively collected among IBD patients hospitalized in a Polish tertiary centre from March 2020 to May 2021. A questionnaire was used assessing the IBD characteristics, other comorbidities, and the course of COVID-19.

Results: Among 350 patients, SARS-CoV-2 infection was diagnosed in 32 (9%). Severe COVID-19, defined as the need for hospitalization, was reported in 6 (19%) and mild in 26 (81%) cases. Compared to the mild COVID-19 course, patients with a severe course more often showed a higher IBD activity (3 points [IQR 2.25-3] vs. 1 point [IQR 0-2] in a semi-quantitative scale, p = 0.002), more often received steroids (67% vs. 11%, p = 0.02), and were not treated with biologics (0% vs. 46%, p = 0.07). There was a correlation between the duration of symptomatic infection and the number of comorbidities (r = 0.4, p = 0.04). No death or short-term COVID-19 complications were reported. In 25% of cases, SARS-CoV-2 infection caused new gastrointestinal symptoms.

Conclusions: IBD is not a risk factor for SARS-CoV-2 infection. Steroids and higher IBD clinical activity may increase the risk of severe COVID-19. The prognosis for COVID-19 in our cohort was good. SARS-CoV-2 infection was a common cause of gastrointestinal symptoms.

查看原文本刊更多论文

2019年炎症性肠病和冠状病毒病的临床过程--前疫苗时代的波兰单中心经验。

导言：关于炎症性肠病（IBD）与中东欧地区 COVID-19 病程关系的数据很少：目的：从波兰一家三级中心的角度评估 IBD 患者感染严重急性呼吸系统综合征冠状病毒-2（SARS-CoV-2）的频率以及 IBD 对 COVID-19 病程的影响：回顾性收集了2020年3月至2021年5月在波兰一家三级中心住院的IBD患者感染SARS-CoV-2的数据。调查问卷用于评估 IBD 特征、其他合并症和 COVID-19 的病程：结果：在 350 名患者中，32 人（9%）确诊感染了 SARS-CoV-2。有 6 例（19%）和 26 例（81%）报告了严重的 COVID-19，严重的 COVID-19 的定义是需要住院治疗，轻度的 COVID-19 的定义是需要住院治疗。与轻度 COVID-19 病程相比，重度病程患者的 IBD 活动度更高（在半定量量表中为 3 点 [IQR 2.25-3] 对 1 点 [IQR 0-2]，p = 0.002），更常接受类固醇治疗（67% 对 11%，p = 0.02），且未接受生物制剂治疗（0% 对 46%，p = 0.07）。无症状感染持续时间与合并症数量之间存在相关性（r = 0.4，p = 0.04）。没有死亡或 COVID-19 短期并发症的报告。在25%的病例中，SARS-CoV-2感染引起了新的胃肠道症状：结论：IBD不是SARS-CoV-2感染的危险因素。结论：IBD 并不是 SARS-CoV-2 感染的危险因素，类固醇和较高的 IBD 临床活动可能会增加发生严重 COVID-19 的风险。我们队列中的 COVID-19 预后良好。SARS-CoV-2 感染是导致胃肠道症状的常见原因。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Przegla̜d Gastroenterologiczny GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

2.20

自引率

7.70%

发文量

审稿时长

6-12 weeks

期刊介绍： Gastroenterology Review is a journal published each 2 months, aimed at gastroenterologists and general practitioners. Published under the patronage of Consultant in Gastroenterology and Polish Pancreatic Club.